Mechanism
SGLT2 (empagliflozin component) and HMG-CoA reductase
Assets acting on this target.
- Class
- Fixed-dose combination tablet: SGLT2 inhibitor + statin — Berlim 25/10 association (empagliflozin 25 mg / rosuvastatin calcium 10 mg), EMS
- Pathway
- Combines renal glucose reabsorption blockade (SGLT2 inhibition) with hepatic cholesterol synthesis inhibition (HMG-CoA reductase) for T2D with dyslipidemia
- Notes
- original target text: SGLT2 (empagliflozin component) and HMG-CoA reductase (rosuvastatin component)
Research
Sign in to access ResearchExplore this mechanism at different depths
Research adds deeper and simplified explanation variants while preserving the same scientific register and source caveats.
0 of 0 assets
No assets match these filters.